Merck MRK

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Led by Drug Group, Bayer Posts Solid 4Q, Setting Up Improving Outlook

      Commentary

      Thu, 26 Feb 2015

      division is well positioned for growth with the recent Merck acquisition. We believe the Merck products were never fully maximized across all regions of the world as Merck lacked scale in the consumer business. Now part

    2. Merck places children's HIV drug in shared non-profit patent pool

      Headlines

      Tue, 24 Feb 2015

      LONDON, Feb 24 (Reuters) - U.S. drugmaker Merck & Co has contributed an HIV medicine for children to an international shared patent pool in a move that should speed the development of cheap paediatric formulations for use in poor countries.

    3. Ex- Merck analyst pleads guilty to U.S. insider trading charges

      Headlines

      Thu, 19 Feb 2015

      NEW YORK, Feb 19 (Reuters) - A former Merck & Co Inc finance analyst pleaded guilty on Thursday to participating in an insider trading scheme in which he passed tips about potential pharmaceutical mergers to a friend who worked at Bank of New York Mellon Corp.

    4. BRIEF- Merck takes full promotional responsibility for Erbitux in Japan

      Headlines

      Fri, 13 Feb 2015

      * Strengthens presence as leading oncology company by taking full promotional responsibility for Erbitux in Japan

    5. Sigma-Aldrich Overcomes Previous Headwinds With Strong 4Q Performance

      Commentary

      Thu, 12 Feb 2015

      with a year ago at 25% when excluding nonrecurring items. We're leaving our $140 fair value estimate in place based on Merck KGaA's planned acquisition of Sigma this year, and we think the firm's narrow economic moat remains intact.

    6. Ex- Merck analyst facing insider trading charges to plead guilty -lawyer

      Headlines

      Mon, 9 Feb 2015

      NEW YORK, Feb 9 (Reuters) - A former Merck & Co Inc finance analyst plans to plead guilty to engaging in an insider trading scheme by tipping a former Bank of New York Mellon Corp employee about...

    7. Low rates, M&A spur flood of pharma debt deals

      Headlines

      Thu, 5 Feb 2015

      NEW YORK, Feb 5 (IFR) - Merck & Co's US$8bn jumbo bond is just the tip of the iceberg of debt supply from the healthcare sector in the months ahead with brand names like Novartis and Pfizer set to compete for investor cash.

    8. UPDATE 3- Merck says hepatitis C treatment to lose "breakthrough" status

      Headlines

      Wed, 4 Feb 2015

      Feb 4 (Reuters) - Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy ..... C because other new drugs are available, a decision that could delay approval of the Merck product by several months.

    9. Merck's 4Q and Guidance Largely Meet Expectations, but Headwinds Arise For Hep C Drugs and Remicade

      Commentary

      Wed, 4 Feb 2015

      Merck reported fourth-quarter results and issued ..... FDA's Breakthrough Therapy Designation for Merck 's hepatitis C treatment (due to recently ..... materially alter our market share expectations for Merck in hepatitis C, and we had already incorporated

    10. Merck issues cautious 2015 forecast, citing dollar

      Headlines

      Wed, 4 Feb 2015

      Feb 4 (Reuters) - Merck & Co on Wednesday reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the negative impact of the stronger dollar, as most of its U.S. rivals have done in making their own cautious forecasts.

    « Prev12345Next »
    Content Partners